Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

High dose rate brachytherapy for prostate cancer: Standard of care and future direction.

Thiruthaneeswaran N, Hoskin PJ.

Cancer Radiother. 2016 Feb;20(1):66-72. doi: 10.1016/j.canrad.2016.01.001. Epub 2016 Jan 22. Review.

PMID:
26811209
2.

Technological advances in radiotherapy for the treatment of localised prostate cancer.

Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, Horwich A.

Eur J Cancer. 2005 Apr;41(6):908-21. Review.

PMID:
15808957
3.

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?

Créhange G, Roach M 3rd, Martin E, Cormier L, Peiffert D, Cochet A, Chapet O, Supiot S, Cosset JM, Bolla M, Chung HT.

Cancer Radiother. 2014 Oct;18(5-6):524-34. doi: 10.1016/j.canrad.2014.07.153. Epub 2014 Sep 2. Review. Erratum in: Cancer Radiother. 2014 Dec;18(8):806.

PMID:
25192626
4.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
5.

Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.

Hsu IC, Pickett B, Shinohara K, Krieg R, Roach M 3rd, Phillips T.

Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):851-8.

PMID:
10705005
6.

High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer.

Challapalli A, Jones E, Harvey C, Hellawell GO, Mangar SA.

Br J Radiol. 2012 Nov;85 Spec No 1:S18-27. doi: 10.1259/bjr/15403217. Review.

7.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
8.

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S, Norlén BJ, Widmark A.

Acta Oncol. 2004;43(4):316-81. Review.

PMID:
15303499
9.
10.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
11.
12.

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.

13.

High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.

Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J.

Prostate Cancer Prostatic Dis. 2006;9(3):245-53. Epub 2006 Jun 20.

PMID:
16786040
14.

Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.

Valero J, Cambeiro M, Galán C, Teijeira M, Romero P, Zudaire J, Moreno M, Ciérvide R, Aristu JJ, Martínez-Monge R.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):386-92. doi: 10.1016/j.ijrobp.2009.01.059. Epub 2009 May 8.

PMID:
19427741
15.

Radical radiotherapy for prostate cancer.

Parker CC, Dearnaley DP.

Cancer Treat Rev. 2003 Jun;29(3):161-9. Review.

PMID:
12787711
16.
17.

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55.

PMID:
15001244
19.

Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.

Pellizzon AC, Nadalin W, Salvajoli JV, Fogaroli RC, Novaes PE, Maia MA, Ferrigno R.

Radiother Oncol. 2003 Feb;66(2):167-72.

PMID:
12648788
20.

Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.

Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, Spencer W, Stromberg J, Huang R, Vicini F.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27.

PMID:
12023135

Supplemental Content

Support Center